376

RIWC 2022
21st Retina International World Congress

RIWC 2022
21st Retina International World Congress

Datum
09.06.2022 - 11.06.2022
Kongress
Reykjavík
Sprache
Englisch
Gebühren ab
21500.00 ISK
Veranstalter
Blindrafélagið
Icelandic Association of the visually impaired (BIAVI)
Organisator

SENA ehf
Hagasmári 1
201 Kópavogur

Retina World Congress is a non-profit organization dedicated to uniting international professionals to foster dialogue and to generate consensus about retinal diseases, emerging technologies and treatments, best practices and clinical research.
The RIWC2022 will be held at the same time and venue as NOK2022 is taking place.
  • Basisinformation
    Datum
    09.06.2022 - 11.06.2022
    Kongress
    Reykjavík
    Sprache
    Englisch
    Gebühren ab
    21500.00 ISK
    Veranstalter
    Blindrafélagið
    Icelandic Association of the visually impaired (BIAVI)
    Organisator

    SENA ehf
    Hagasmári 1
    201 Kópavogur

  • VERANSTALTUNGSORT
    HARPA Concert Hall and Conference Centre
    Austurbakki 2
    101 Reykjavík, IS
  • Programm
    Thursday 9th June

    17:00 - 19:00
    Welcoming ceremony

    17:30 - 18:30
    K.1.1 Keynote: Phenotyping and Genotyping in inherited retinal diseases. - Speaker: Prof. Bart Leroy, University of Ghent, Gent, Belgium. Ask to include Refsum and other metabolic diseases.
     
    Friday 10th June

    08:30-10:00
    P.2.1 Age related macular Degeneration. - Moderator: Jóhann Ragnar Guðmundsson

    08:30-08:50
    The MacuStar project - Robert Finger, Department of Ophthalmology, University of Bonn, Germany - Confirmed

    08:50 – 09:05
    AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy and beyond.
    Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway. Confirmed

    09:05 – 09:15 Off-label use of Avastin: Scandinavian disparities.
    Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden Confirmed

    09:15 – 09:25 The risk of extending AMD treatment.
    Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden. ? Restrictions for travel

    09:25 – 09:35 The Swedish Macula Register.
    Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden. Confirmed

    09:35 – 09:50 AMD Epidemiology and Genetics. What is important!
    Speaker: Prof. emeritus Friðbert Jónasson, University of Iceland, Iceland. Confirmed. There will be a change of the title

    09:50 – 10:00 QnA.

    08:30 – 10:00 L.2.1 Retinal degenerations. Clinical aspects.

    Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada.Confirmed

    08:30 – 08:50 Clinical aspects of IRD.
    Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada. Confirmed

    08:50 – 09:10 Clinical aspects of inherited macular degenerations.
    Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. Confirmed

    09:10 – 09:30 Syndromic forms of IRD.
    Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France. Confirmed

    09:30 – 09:50 The genetic testing landscape
    Speaker: Avril Daly, Retina International, Dublin, Ireland Confirmed

    09:50 – 10:00 QnA.

    10:00 – 10:30 Coffee break.

    10:30 – 11:30 P.2.2 Assessment of Endpoints in clinical studies.

    Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellström, Lund, Sweden. Confirmed

    10:30 – 10:50 Experiences with Luxturna.
    Speaker: Prof.Line Kessel, Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark Confirmed

    10:50 – 11:10 Paediatric specificities in trials.
    Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada. Confirmed

    11:10 – 11:30 Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT).

    Speaker: Dr. Daniel Chung, DO, MA, Philadelphia, USA Confirmed Daniel.chung@sparingvision.com

    Where to put gene agnostic approaches?

    10:30 – 11:30 L.2.2 Retinal degenerations – the genetics.

    Moderator: Prof. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland. Confirmed

    10:30 – 10:50 Pattern of inheritance – easy to understand.
    Speaker: Dr. Eirný Þórólfsdóttir National University Hospital, Reykjavík, Iceland. Confirmed

    10:50 – 11:10 Understanding the results – a difficult task.
    Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland.Confirmed

    11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes. Speaker: Daníel Þorsteinsson. Confirmed

    11:20 – 11:30 ABCA4 related IRDs
    Speaker: Frans Cremers, Radboud University, Nijmegen, Netherlands Confirmed

    11:30 – 12:00 K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception.
    Speaker: Christina Fasser, former president of the Retina International, Zurich, Switzerland. Confirmed

    12:00 – 13:30 Lunch

    13:30 – 14:00 K.2.2
    Keynote: Innovations in Ophthalmology.
    Dr. Sabri Markabi NOT confirmed. Masayo Takahashi?Yes, switch with Christina

    14:00 – 15:00 P.2.3 Phenotype-Genotype Correlations in IRD

    Moderators: Josephine Prener Holtan MD, Oslo University Hospital, Oslo, Norway, and Prof. Bart Leroy, Ghent, Belgium. Confirmed

    14.00 – 14.10 Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene.
    Speaker: Kristian Lisbjerg, MD, Department of Ophthalmology, Copenhagen University Hospital, Denmark.Confirmed

    14.10 – 14.20 Genetic basis and phenotypic characterization of Danish patients with Achromatopsia.
    Speaker: Mette K.G. Andersen,MD, Ophthalmologist at Department of Ophthalmology, Copenhagen University hospital, Rigshospitalet-Glostrup, Denmark.Confirmed

    14.20 – 14.35 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective.
    Speaker: Ragnhild Jansson Wivestad, MD, Department of Ophthalmology, Haukeland University Hospital, Norway. Confirmed

    14.35 – 15.00 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe.
    Speaker: Professor Helene Dollfuss, MD, PhD, Service de Génétique Médicale, Hôpital de Hautepierre, Strasbourg, France. Confirmed

    14:00 – 15:00 L.2.3 Basics of stem cell and gene-based therapies.

    Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA Confirmed 14:00 – 14:20 Overview of on-going clinical trials with stem cells

    Speaker: Prof. Goran Petrovski.Confirmed 14:20 – 14:35 Stem Cell Based Trials for AMD

    Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA Confirmed 14:35 – 14:50 Clinical trial in opto-genetics.

    Speaker: Prof. Isabelle Audo, INSERM, Paris, France. Confirmed
    14:50 – 15:00 How to discriminate between real treatments offers and quacks.

    Speaker: Martin Smedstad Oslo, Norway. Change title 15:00 – 15:30 Coffee break.

    15:30 – 16:00 K.2.3
    Keynote: Restoration of vision
    Speaker: Prof. Mark S. Humayun University of Southern California, Los Angeles, USA. Confirmed

    16:00 – 17:00 P.2.4. Innovations in Ophthalmology.

    Moderators: Christina Fasser and Prof. Einar Stefánsson. Program not ready

    16:00 – 17:00 L.2.4 Rehabilitation and mobility training. Session confirmed Moderators: Vala Jóna Garðarsdóttir and Rósa María Hjörvar Iceland.

    16:00 – 16:15 Mobility training and mobility tools.
    Speaker: Vala Jóna Garðarsdóttir. National institute for the blind in Iceland.
    16:15-16:30 Reading with auxiliary aids.
    Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland.
    16:30-16:45 The assistive technology, aps etc.
    Speakers: Baldur Snær Sigurðsson and Hlynur Þór Agnarsson.
    16:45 – 17:00 Coping with visual and hearing impairment.
    Speakers: Halla Dís Hallfreðsdóttir and Elín Yr Hafdisardóttir Arnardóttir.
    Saturday 11th June

    08:30–10:00 P.3.1 New Developments in IRD.

    Moderator: Prof. Michael Larsen. Confirmed
    08:30-08:50 Accessing Genetic Testing for IRDs: The Patient Perspective.

    Speaker: Fiona Waters, Retina International, Dublin, Ireland Confirmed 08:50-09:10 ABCA4 retinal dystrophies

    Speaker: Frans Cremers, Radboud University, Nijmegen, Netherlands Confirmed 09:10- 09:30 Ragnheidur Bragadottir and Josephine Prener Holtan: Luxturna treatment

    in Norway Confirmed

    09:30-10:00 Masayo Takahashi: the first clinical trial with iPScells Takahashi as keynote, Koenekoop instead: Gene therapy of Choroideraemia and X-linked retinitis pigmentosa – lessons to be learned. Confirmed

    08:30-10:00 L.3.1 Clinical trials and therapies from a patient’s perspective.

    Moderator: Martin Smedstad, Oslo, Norway. Is session confirmed? 08:30 – 08:50 Overview and future on on-going clinical trials.

    Speaker Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada. 08:50 – 09:10 RPE65 – the first gene therapy on the market.

    Speaker: Dr. Daniel Chung, Philadelphia, USA. Change to Line Kessel 09:10 – 09:30 Oligonucleotides – a hope for all?

    Speaker: Prof. Bart Leroy, Gent University, Ghent, Belgium. Confirmed 09:30 – 09:50 My personal experience of gene therapy.

    Speaker: Camilla Jensen, Oslo, Norway Not formally confirmed 10:00 – 10.30 Coffee break.

    10:30 – 12:00 P.3.2 Stem cells and cell-based therapies of retinal diseases. Moderator Dr. Goran Petrovski, Oslo, Norway. Confirmed

    10;30 – 10:45: Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside.
    Speaker: Prof. Kapil Bharti (NIH/NEI), Bethesda, USA. Confirmed

    10:45 – 11:00 Towards stem cell-based therapy in retinal degeneration. Speaker: Anders Kvanta Stockholm, Sweden. Confirmed

    11:00 – 11:30 Subretinal implantation of primary human RPE cells in minipig eyes. Speaker: Dr. Goran Petrovski, Oslo, Norway.

    11:30 – 12:00 RB asks Koenekoop to give a presentation?

    10:30 – 12:00 L 3.2 Retina International – the global challenges.

    Moderator: Kristinn Halldor Einarsson, Iceland.

    Christina and Avril will arrange the program

    12:00 – 13:00 Lunch.

    13:00 – 14:00 K.3.1 Keynote: Gene based therapies of retinal diseases. Speaker: Prof. Artur Cideciyan, University of Pennsylvania, Philadelphia, USA. Confirmed

    14:00 – 15:00 P.3.3 Gene based therapies of retinal diseases.
    Moderator Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland. Send her e-mail

    14:00 – 14:15 CPK850 gene therapy in RLPB1 patients.
    Speaker: Prof. Anders Kvanta, Karolinska Institute, Stockholm, Sweden Confirmed

    14:15 – 14:30 (Retinal gene therapy trials – investigators point of view.
    Speaker: Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland.) Sankila not willing to give a talk due to insufficient/disappointing results. Chung: Agnostic gene therapy approaches?

    14:30 – 14:45 Retinal gene therapy in choroideremia patients – surgical aspects. Speaker: Prof. Ilkka Immonen, Helsinki University Hospital, Helsinki, Finland.

    14:45 – 15:00 Gene therapy of Usher syndrome.
    Speaker: Prof. Isabelle Audo, Institute de la Vision, Paris, France. Confirmed

    14:00 – 15:00 L.3.4 Programme in Icelandic for the public. Kristinn will find panellists and a moderator

    15:00 Closing ceremony. Zrenner confirmed

  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    105.000,00 ISK
    Early Bird bis 15.03.2022
    85.000,00 ISK
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    26.500,00 ISK
    Early Bird bis 15.03.2022
    21.500,00 ISK
    Studenten/-innen
    Gebühren ab
    26.500,00 ISK
    Early Bird bis 15.03.2022
    21.500,00 ISK
    Retina International members and patients fee: 37.000,00 ISK (EB), 43.000,00 ISK
    Youth program participants fee: 21.000,00 ISK (EB), 26.500,00 ISK
  • Buchung / Anmeldung

    Please contact the organizer for further information.

    You are the organizer?
    Would you like to link your online registration here?
    Please contact our sales team for an individual offer:
    +49 (0) 30 403 6422-0 (phone) or info@eyefox.com (e-mail).

  • Zertifizierung
    Zertifizierung unbekannt

Veranstaltung teilen